Feline lower urinary tract disease (FLUTD) and its most common form, feline idiopathic cystitis (FIC), remain therapeutic challenges because the underlying mechanisms are incompletely understood. A recent study by Cunha and colleagues (2026) provides the first detailed map of cannabinoid receptor type 1 (CB₁R) and type 2 (CB₂R) in the urinary bladder of domestic cats, offering a new anatomical framework that could inform future pharmacological strategies targeting the endocannabinoid system (ECS) in veterinary urology.
Clinical Context and Rationale
FLUTD encompasses a spectrum of disorders—including urolithiasis, bacterial infection, neurogenic dysfunction and, most prevalently, FIC—that together affect a large proportion of pet cats. The pathophysiology of FIC is multifactorial, involving stress‑related neuroendocrine dysregulation, altered sensory processing, and bladder inflammation. In other mammals, the ECS—comprising endogenous ligands (anandamide, 2‑arachidonoylglycerol), metabolic enzymes, and the G‑protein‑coupled receptors CB₁R and CB₂R—modulates micturition thresholds, smooth‑muscle contractility, afferent nerve activity and inflammatory responses. Experimental work in rodents has shown that activation of CB₁R or CB₂R can reduce bladder overactivity and inflammation, yet similar pharmacological effects have not been consistently reproduced in larger species such as dogs, pigs, monkeys or humans. The absence of any data on the feline bladder left a critical gap for researchers exploring cannabinoid‑based interventions in cats.
Study Design
The investigation was an observational, post‑mortem, cross‑sectional analysis of eleven privately owned domestic cats whose owners donated the animals for research after death or euthanasia unrelated to urinary disease. Inclusion required no clinical history of FLUTD and a cause of death that did not involve the urinary tract. Ages ranged from one to eighteen years (mean 8.5 ± 5.6 years). Bladders were harvested within four hours of death, kept at +4 °C, and the urothelium and detrusor muscle were dissected separately.
Three complementary techniques were employed:
- RT‑qPCR to quantify CNR1 (CB₁R) and CNR2 (CB₂R) mRNA in urothelium and detrusor samples preserved in RNALater (n = 4). The housekeeping gene YWHAZ was validated as a stable reference; cypA proved unsuitable because it was undetectable in fixed tissue.
- Western blotting on whole‑bladder homogenates to verify the presence of CB₁R and CB₂R proteins at their expected molecular weights.
- Immunofluorescence (IF) with quantitative mean‑intensity analysis (gMEAN) on cryosections (n = 11) to map the cellular distribution of each receptor, including double‑labeling with the sensory neuronal marker Substance P (SP).
Statistical comparisons between urothelium and detrusor intensities used paired t‑tests with a significance threshold of p < 0.05.
Gene Expression Findings
- CB₂R (CNR2) transcripts were detected in all four RNALater‑preserved cats, both in urothelium and detrusor. The data passed normality (Shapiro‑Wilk) and equal‑variance (Levene) tests, and a paired t‑test showed no significant difference between the two layers (p = 0.09).
- CB₁R (CNR1) mRNA was undetectable in every sample, regardless of tissue compartment.
The inability to amplify CNR1 despite robust detection of the reference gene suggests that basal CNR1 transcription in a healthy feline bladder is extremely low, below the detection limit of conventional RT‑qPCR.
Protein Confirmation
Western blot analysis of whole‑bladder extracts revealed immunoreactive bands at approximately 50 kDa for CB₁R and 40 kDa for CB₂R, matching the predicted molecular weights for the feline proteins. These results confirm that both receptors are present at the protein level, even when CNR1 transcripts are not measurable by qPCR.
Cellular Distribution by Immunofluorescence
Quantitative IF highlighted a striking compartmentalization:
| Receptor | Predominant Layer | Qualitative Pattern | Mean gMEAN (± SD) – Urothelium | Mean gMEAN (± SD) – Detrusor | Statistical Outcome |
|---|---|---|---|---|---|
| CB₁R | Detrusor & vasculature | Sparse in urothelium; moderate in smooth‑muscle cells; bright in endothelial and arterial smooth‑muscle cells; present in intramural neurons | 1,966 ± 1,656 | 5,860 ± 3,293 | D > U, p = 0.0006 |
| CB₂R | Urothelium (umbrella cells) | Strong cytoplasmic staining of superficial umbrella cells; decreasing intensity in intermediate cells; minimal in basal cells; bright in intramural neurons and SP‑positive fibers; faint in detrusor smooth muscle | 53,357 ± 10,634 | 14,499 ± 5,709 | U > D, p < 0.0001 |
CB₁R was most evident in vascular endothelial cells, arterial smooth muscle, and intramural neuronal elements, suggesting a role in regulating bladder blood flow and local neural signaling. In contrast, CB₂R was concentrated in the superficial urothelium—particularly the large umbrella cells that interface directly with urine—and in sensory nerve fibers marked by Substance P. A distinct population of elongated, CB₂R‑positive cells was observed in the detrusor near SP‑positive fibers; the authors hypothesize these may be interstitial cells of Cajal‑like cells or myofibroblast‑like cells, though no specific markers were applied to confirm their identity.
Reconciling mRNA and Protein Discrepancies
The most unexpected observation was the detection of CB₁R protein despite the complete absence of CNR1 transcripts. The authors propose two non‑exclusive explanations:
- Low‑level transcription that falls below the RT‑qPCR detection threshold but is sufficient to generate detectable protein over time.
- Axonal transport of CB₁R synthesized in neuronal cell bodies outside the bladder (e.g., dorsal root ganglia) and delivered to intramural nerve terminals.
They recommend future studies employing more sensitive RNA quantification methods—such as digital PCR or RNA‑seq—to resolve this discrepancy.
Limitations and Unanswered Questions
While the anatomical mapping is comprehensive, several gaps remain:
- Disease Context: All samples derived from cats without FLUTD; thus, the study does not reveal how receptor expression changes during cystitis, FIC or other bladder pathologies.
- Functional Correlation: No physiological assays (e.g., organ bath studies, in‑vivo cystometry) were performed to determine whether activation or blockade of CB₁R or CB₂R modifies bladder contractility, afferent signaling or inflammatory markers in cats.
- Cellular Identity of CB₂R‑Positive Interstitial Cells: Without immunostaining for definitive markers (c‑Kit, vimentin, PDGFRα), the exact nature of the elongated CB₂R‑positive cells remains speculative.
- Pharmacological Translation: Prior cross‑species work has shown that synthetic cannabinoids effective in rodents may fail in larger mammals. The presence of CB₁R and CB₂R in feline bladder tissue does not guarantee that existing cannabinoid agonists will produce therapeutic effects in cats.
Addressing these points will be essential before cannabinoid‑based drugs can be rationally applied to feline urinary disorders.
Implications for Veterinary Medicine
The clear localization of CB₂R to the urothelial surface and to sensory nerve endings positions this receptor as a promising target for modulating bladder sensation and inflammation—key components of FIC pathology. Conversely, the vascular and neuronal enrichment of CB₁R suggests potential involvement in bladder blood flow regulation and neuromodulation. The divergent distribution patterns underscore that selective activation of CB₂R, perhaps with a peripherally restricted agonist, could attenuate urothelial irritation without eliciting central nervous system effects. However, the lack of CNR1 transcription and the uncertain functional relevance of CB₁R in the feline bladder caution against assuming efficacy based solely on receptor presence.
Future research should combine the anatomical insights from this study with functional assays in both healthy and diseased cats, and explore whether modulation of the ECS can alleviate clinical signs of FLUTD. Until such data are available, the therapeutic promise of cannabinoids in feline urology remains an intriguing hypothesis awaiting experimental validation.